A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-α1 in patients with lung cancer

Journal of Biological Response Modifiers

Volumn 4, Issue 2, 1985, Pages 147-158

  Schulof, Richard S ^a   Lloyd, Margaret J ^a   Cleary, Patricia A ^b   Palaszynski, Susan R ^a   Mai, Dao A ^a   Cox, John W ^a   Alabaster, Oliver ^a   Goldstein, Allan L ^b  

^a Division of Hematology and Oncology ^*  (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Non small cell lung cancer; Phase I II trials; Radiotherapy; Serial immune studies; Thymosin 1

Indexed keywords

PLACEBO; THYMOSIN; THYMOSIN ALPHA1;

BLOOD AND HEMOPOIETIC SYSTEM; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE; DRUG EFFICACY; DRUG SCREENING; DRUG TOXICITY; HISTOLOGY; HUMAN; IMMUNE RESPONSE; INTOXICATION; LUNG CANCER; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; T LYMPHOCYTE; THERAPY;

ADJUVANTS, IMMUNOLOGIC; AGED; DRUG EVALUATION; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION INJURIES; RANDOM ALLOCATION; THYMOSIN;

EID: 0022362208     PISSN: 07326580     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1979:191-205.
2. Glasgow AH, Nimberg RB, Menzoian JO, et al. Association of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer. N Eng J Med 1974;291:1263-7.
3. Gialiano AE, Rangel DM, Golub SH, Holmes EC, Morton DL. Serum mediated immunosuppression in lung cancer. Cancer 1979;43:911-24.
4. Low TLK, Thurman GB, Chincarini C, et al. Current status of thymosin research: evidence for a family of thymic factors that control T cell maturation. Ann NY Acad Sci 1979;332:33-48.
5. Schulof RS, Goldstein AL. Thymosins and other thymic hormones. In: Hadden JW, Stewart WE II, eds. Lymphokines. Clifton, New Jersey: Humana Press, 1981;397-423.
6. Goldstein AL, Low TLK, Thurman GB, et al. Thymosins and other hormone-like factors of the thymus gland. In: Michich E, ed. Immunological approaches to cancer therapeutics. New York: John Wiley & Sons, 1982:137-90.
7. Schulof RS, Goldstein AL. Clinical applications of thymosin and other thymic hormones. In: Thompson RA, Rose NR, eds. Recent advances in clinical immunology. New York: Churchill Livingstone, 1983;243-86.
8. 1. J Am Chem Soc 1978;101:253-8.
9. 1. Int J Pept Protein Res 1980;15:1-5.
10. 1. J Biol Resp Modif 1982;1:35-41.
11. 1. J Biol Resp Modif 1983;2:139-50.
12. Fabrega R, Pinsky C, Braun D Jr, Chung T, Krown S, Oettgen H. Phase I trial of thymosin fraction 5 in advanced cancer patients. Proc Am Assoc Cancer Res 1983:23:126.
13. Wara WM, Neely MH, Flippin LJ, Wara DM. Phase I trial using thymosin fraction 5 in renal cancer-NCOG report. In: Goldstein AL, ed. Thymic hormones and lymphokines. New York: Plenum Press, 1984:587-91.
14. Smalley RV, Talmadge J, Oldham RK. Thurman GB. The thymosins-preclinical and clinical studies with fraction 5 and a,. Cancer Treat Rev 1984;11:69-84.
15. 1 administration in man: a prototypic thymic hormone efficacy trial in patients with lung cancer. In: Serrou B, Rosenfeld C, Daniels JC, Saunders JP, eds. Current concepts in human immunology and cancer immunodulation. Amsterdam: Elsevier Biomedical Press, 1982;545-52.
16. 1 in patients with lung cancer. In: Hobbs JR, ed. Serono Symposium on Thymic Factor Therapy. New York: Academic Press, 1985 (in press).
17. 1 administration in patients with lung cancer: preliminary results. In: Goldstein AL, ed. Thymic hormones and lymphokines. New York: Plenum Press, 1984:601-13.
18. Thomas JW, Coy P, Lewis HS, Yuen A. Effect of therapeutic irradiation on lymphocyte transformation in lung cancer. Cancer 1971;27:1046-50.
19. Dellon AL, Potvin C, Chretien PB Thymus-dependent lymphocyte levels during radiation therapy for bronchogenic and esophageal carcinoma: correlation with clinical course in responders and non-responders. Am J Roentgenol Radium Ther Nucl Med 1975;123:500-11.
20. Stratton JA, Byfield PE, Byfield JE, Small RC, Benfield J, Pilch Y. A comparison of the acute effects of radiation therapy, including or excluding the thymus, on the lymphocyte subpopulations of cancer patients. J Clin Invest 1975;56:88-97.
21. Schulof RS, Chorba TL, Cleary PA, Palaszynski SR, Alabaster O, Goldstein AL. T cell abnormalities after mediastinal irradiation for lung cancer: the in vitro influence of synthetic thymosin a,. Cancer 1985 (in press).
22. Cohen MH, Chretien PB, Ihde DC, et al. Thymosin fraction V and intensive combination chemotherapy prolonging the survival of patients with small-cell lung cancer. JAMA 1979;241:1813-15.
23. Wara WM, Neely MH, Amman AJ, Wara DM. Biologic modification of immunologic parameters in head and neck cancer patients with thymosin fraction 5. In: Goldstein AL, Chirigos MA, eds. Lymphokines and thymic hormones: their potential utilization in cancer therapeutics. New York: Raven Press, 1981:257-62.
24. World Health Organization. The World Health Organization histological typing of lung tumors. 2nd ed. Am J Clin Pathol 1982;77:123-36.
25. 1 by fragment condensation using tert-butyl side-chain protection. Proceedings of the 8th American Peptide Symposium. Tucson, Arizona. 1985 (in press).
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
27. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1959;50:163-76.
28. Wara DW. Thymic hormones in primary immunodeficiency. In: Bach JF, ed. Clinics in immunology and allergy. London: WB Saunders, 1983;3:179-83.